May 10, 2014 by Amy HoWill New Regulations on E-Cigs Hurt Big Tobacco?New regulatory proposals on tobacco questionable on both passage and impact
Apr 24, 2014 by Amy HoSarepta's Still a Gamble, Even With FDA ReversalWill Sarepta finally get approval for eteplirsen?
Apr 15, 2014 by Amy HoCan Merck & Co. Inc. and Bristol-Myers Squibb Co. Dethrone Gilead Sciences Inc. for Hep C Combo?Merck plays catch-up while Bristol-Myers looks global.
Apr 4, 2014 by Amy HoWhat's Next for Cubist Pharmaceuticals Inc. and Durata Therapeutics, Inc.?Two drugs are hot on Pfizer’s tail.
Apr 3, 2014 by Amy HoDoes Amgen Have the Next Lipitor on Its Hands?Amgen leads the PCSK9-blocker class of cholesterol drugs.
Mar 31, 2014 by Amy HoFDA Review Incoming: Will Mannkind Finally Succeed?Could a third rejection may be looming for MNKD inhalable insulin?
Mar 18, 2014 by Amy HoTrouble Ahead for Gilead and Sovaldi?Idenix files suit atop $9 billion sales estimates for Gilead's Sovaldi
Mar 11, 2014 by Amy HoHow Will This Latest Setback Affect Eli Lilly?Concerns over Boerhringer Ingelheim plant delay approval of key diabetes agent
Mar 7, 2014 by Amy HoCancer Immunotherapy Race Stays UnpredictableMerck, Bristol-Myers and Roche head the race to pioneer PD-1 therapies.
Mar 4, 2014 by Amy HoIs This Drug Enough To Revive Hope in Eli Lilly's Pipeline?Eli Lilly struggles to gain approval and regain diabetes market share.
Mar 4, 2014 by Amy HoWhy Would Roche Return to the Antibiotics Market?Roche’s new deal with Discuva marks major private sector commitment to antibiotic development
Mar 3, 2014 by Amy HoBristol-Myers Closing in on Gilead in Hepatitis C RaceNew breakthrough designation could help Bristol-Myers compete more quickly with market-leader Gilead.
Feb 11, 2014 by Amy HoGilead Combination Hepatitis C Filing Solidifies Its LeadershipAbbVie and Bristol-Myers unlikely to catch Gilead in race for oral hep C combination therapy
Feb 11, 2014 by Amy HoAstraZeneca Struggles to Meet ExpectationsCEO Pascal Soriot is fighting an uphill battling winning investors on pipeline.
Feb 11, 2014 by Amy HoAntidepressant R&D Takes Another Hit with J&JMultiple approaches to depression treatment fail trials
Feb 4, 2014 by Amy HoCompanies Limp Towards a Duchenne Treatment – Is There Hope of a Finish Line?2014 starts a dismal year for Duchenne prospects by Sarepta, Prosensa, PTC and Retrophin
Feb 4, 2014 by Amy HoAbbVie's Challenge to Gilead in Hepatitis C TherapiesNew clinical data from AbbVie spice up hepatitis C market and prospects for the company
Feb 2, 2014 by Amy HoCould Ariad Be Set for a Comeback?Ariad's troubled drug Iclusig undergoes an official return to market.
Feb 2, 2014 by Amy HoFierce Competition in the Diabetes Drug MarketGSK, Eli Lilly and Sanofi fight for already-crowded diabetes market share
Jan 27, 2014 by Amy HoRoche's Schizophrenia Drug Fails Phase III Trials, but Is Not Yet ScrappedWell-diversified and restructured Roche handles a minor bitopertin setback.
